Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06526000 · ClinicalTrials.gov registry record
Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies
A clinical trial, sponsored by Novartis.
- Completed
- Registry status
- 326
- Enrollment target
NCT06526000 is a clinical trial that has completed, run by Novartis. The registered enrollment target is 326 participants.
The verdict
NCT06526000 has completed, sponsored by Novartis.
- COMPLETED
- Registry status
- 326 participants
- Enrollment target
Study Summary
This was an observational retrospective cohort study using electronic medical records (EMRs) to study immunoglobulin levels over time among patients with relapsing forms of multiple sclerosis (MS) newly initiating anti-CD20 monoclonal antibody treatment in clinical practice. The index date was defined as the date of anti-CD20 drug initiation during the study period. The baseline period was defined as 12 months prior to the index date.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 326 participants |
| Start Date | 2022-10-11 |
| Est. Completion | 2024-02-28 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06526000
The ClinicalTrials.gov registry entry for NCT06526000 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 326 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis, which has 265 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT06526000 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06526000 about?
NCT06526000 is a clinical study titled "Study to Assess Changes in Immunoglobulins in Patients With Relapsing Multiple Sclerosis Treated With Anti-CD20 Therapies". This was an observational retrospective cohort study using electronic medical records (EMRs) to study immunoglobulin levels over time among patients with relapsing forms of multiple sclerosis (MS) newly initiating anti-CD20 monoclonal antibody treatment in clinical practice. The index date was defi...
What is the current status of trial NCT06526000?
This trial is currently completed. The enrollment target is 326 participants. The study started on 2022-10-11. Estimated completion is 2024-02-28.
Who is sponsoring clinical trial NCT06526000?
This trial is sponsored by Novartis, which has 265 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.